Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Discusses Clinical Program in New Interview with CFN Media

Posted by AGORACOM-JC at 9:19 AM on Tuesday, February 14th, 2017

Tbp large

  • Exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program
  • Interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer

SEATTLE, WA–(Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. (OTC PINK: GRPOF) (CNSX: TBP) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance its PPP001 clinical trial. During the meeting, the FDA provided all the necessary guidance on the design of a Phase I clinical trial on healthy volunteers and its overall development program. The meeting further demonstrates the agency’s willingness to continue the clinical trial to develop a dried marijuana prescription drug.

PPP001 is a dried cannabis product with 9.5% tetrahydrocannabinol (“THC”) and 2% cannabidiol (“CBD”) that is being developed as a prescription drug that will meet the FDA’s high bar for quality and manufacturing. The company’s goal is to be the first to achieve reimbursement from insurance companies for the cost of the prescription, which could prove to be a game-changer for would-be medical marijuana patients that cannot afford the drug.

Tetra Bio-Pharma recently partnered with Sante Cannabis in Montreal to assist in developing its clinical trials. As a leading private medical marijuana clinic, the organization has years of experience in educating patients and ensuring the optimal benefits. The company aims to leverage this expertise to ensure that its clinical trials are properly designed to achieve desired outcomes while helping achieve the organization’s goal of lowering costs for patients.

Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-moves-closer-to-clinical-trials/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

 

VIDEO FEATURE: New Age Metals – 121 Mining Investment Cape Town 2017 $NAM.ca

Posted by AGORACOM-JC at 4:32 PM on Monday, February 13th, 2017

Namaste Applies to Trade on OTCQB $N.ca

Posted by AGORACOM-JC at 10:48 AM on Monday, February 13th, 2017

Nlogo

  • Applied for approval from OTC Markets Group to trade the Company’s common shares on the OTCQB Venture Market
  • Company will provide further updates to investors relating to the trading of its common shares on OTCQB in due course

VANCOUVER, BRITISH COLUMBIA–(Feb. 13, 2017) - Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) is pleased to announce that it has applied for approval from OTC Markets Group to trade the Company’s common shares on the OTCQB Venture Market. Approval from OTC Markets Group is subject to the approval of Form 211 by FINRA, which has been filed by Canaccord Genuity Inc. as a market maker in the common shares, and is currently pending approval. The Company will provide further updates to investors relating to the trading of its common shares on OTCQB in due course.

Sean Dollinger, President and CEO of Namaste, comments: “Namaste has developed a significant US presence over the last year and believes trading our shares on the OTCBQ is a natural way to broaden awareness of our company with US investors. We look forward to completing this process and generating awareness of our company in the US markets.”

About OTC Markets Group Inc.

OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 US and global securities. Through OTC Link® ATS, the company connects a diverse network of broker-dealers that provide liquidity and execution services. The company enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 e-commerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to several factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+ 1 (786) 389-9771
info@namastevapes.com
www.namastetechnologies.com

Pacific North West Capital Announces Effective Date of Share Consolidation and Name Change $PFN.ca

Posted by AGORACOM-JC at 4:35 PM on Tuesday, January 31st, 2017

Hublogo1 copy

  • Received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc.
  • Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New Age Metals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”

Vancouver, British Columbia / January 31, 2017 - Pacific North West Capital Corp. (“PFN”) (TSXV: PFN OTCQB: PAWEF FSE: P7J) announces that further to news release of January 25, 2017, PFN has received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc. (the “Company”). Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New AgeMetals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”.

Letters of transmittal will be sent to the registered shareholders providing instructions to surrender the share certificates evidencing their pre-consolidated common shares for replacement certificates of New Age Metals Inc. representing the number of post-consolidated common shares they are entitled to as a result of the consolidation. Until surrendered, each certificate representing the pre-consolidated common shares will be deemed to represent the number of post-consolidated common shares of New Age Metals Inc. that the holder thereof is entitled to as a result of the consolidation. The Company will not be issuing fractional shares as a result of the consolidation. Instead, all fractional shares equal or greater to one-half will be rounded to the next whole share.

The Company’s website, newagemetals.com, is currently under construction and is slated for completion in the upcoming days. During this transition period, please visit pfncapital.com for more information about the Company’s projects.

On behalf of the Board of Directors

“Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

INTERVIEW: American Creek Discusses the Invaluable addition of Jeff Kyba P.Geo to the Team $AMK.ca

Posted by AGORACOM-JC at 8:10 AM on Tuesday, January 31st, 2017

  • American Creek Resources is a precious metals exploration company with an impressive portfolio of high-potential gold and silver projects in British Columbia.  These include properties in B.C.’s prolific Golden Triangle, one of the richest areas of mineralization in the world.
  • MTJLS Mineralization in the Treaty Creek claims area lies within the same broad hydrothermal system that generated the several deposits on the Seabridge Gold KSM and the Pretivm Brucejack properties that lie immediately southwest of the Treaty Creek claims
  • So far over 130 million ounces of gold, 800 million ounces of silver and 20 billion pounds of copper (all categories included), representing one of the greatest concentrations of metal value on the planet, have been delineated within the geological system shared by KSM, Brucejack, and Treaty Creek.

Hub On AGORACOM / Corporate Profile / Watch Interview!

Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with FDA on PPP001 $TBP.ca

Posted by AGORACOM-JC at 10:21 AM on Monday, January 30th, 2017

Tbp large

  • Completed its pre-IND meeting with the USA Food and Drug Administration  for its PPP001 dried cannabis drug product
  • Meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research
  • FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements

OTTAWA, ONTARIO–(Jan. 30, 2017) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).

The FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements. Dr. Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, commented “We could not be more pleased, as the FDA guidance gave us a clear path to progress from early to late phase clinical development. Adhering to the US FDA regulations is part of Tetra Bio-Pharma’s dedication to the commercialization of Cannabis as a prescription controlled drug and the corporations plan to seek reimbursement by insurers for patients.”

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 689-0714

Namaste Announces Record Quarterly Revenue of over $2M for Q1 2017 $N.ca

Posted by AGORACOM-JC at 9:51 AM on Monday, January 30th, 2017

Nlogo

  • Recorded record quarterly revenue of $2,087,188, an increase of 77.6% from the first quarter of 2016;
  • Generated gross profit of $683,016, an increase of 75.9% from the first quarter of 2016;
  • Expanded the customer list to over 250,000 individuals producing monthly traffic of approximately 600,000 site visits in November

VANCOUVER, BRITISH COLUMBIA–(Jan. 30, 2017) - Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis, and certification of the quarterly filings for the first quarter of fiscal 2017. The statements for the period can be accessed on SEDAR at www.sedar.com.

The operational and financial highlights for the period include the following:

  • Recorded record quarterly revenue of $2,087,188, an increase of 77.6% from the first quarter of 2016;
  • Generated gross profit of $683,016, an increase of 75.9% from the first quarter of 2016;
  • Expanded the customer list to over 250,000 individuals producing monthly traffic of approximately 600,000 site visits in November;
  • Closed the acquisition of the assets of URT1 Limited, which comprised its Everyonedoesit business (“Everyonedoesit”) and raised approximately $3.5 million of capital; and
  • Appointed experienced members to the management team and board.

Financial Results

During the financial reporting period from September 1, 2016 to November 30, 2016, the Company focused efforts on further expanding its traffic and customer base, growing revenues, integrating the asset acquisitions of VaporSeller and Everyonedoesit, and securing capital to expand operations. Because of these focused initiatives, the Company achieved the following financial results:

  • Net revenue of $2,087,188 (Q1 2016 – $1,175,341), an increase of 77.6% as compared to the first quarter of 2016. These financial results include net revenues for a 44-day period from the Everyonedoesit asset acquisition, which produced revenue of $316,460. On a gross basis (prior to adjustments for refunds, discounts and charge backs), the revenues for the period were $2,460,738, an increase of $373,550 to net revenues. These adjustments are anticipated to normalize as the Company has now integrated the acquisition of VaporSeller and URT1, which is anticipated to result in a higher net revenue going forward.
  • Cost of sales of $1,404,172 (Q1 2016 – $787,008), which resulted in a gross profit of $683,016 (Q1 2016 – $388,333). As a percentage of sales, the gross margin was 32.7% compared to 33.0% in the first quarter of 2016. Going forward, the Company is optimizing its product mix to include higher margin glassware, private label products such as the Gurutm and related product accessories, products sourced from larger volume manufacturers, and driving higher average purchase prices from the VaporSeller and URT1 acquisitions.
  • Operating costs of $1,580,087 (Q1 2016 – $513,977), an increase of 207.4% as compared to the first quarter of 2016. This increase in operating costs includes non-cash and currency expenses of $71,416. These costs relate to share based compensation and foreign exchange movements in the Company’s source currencies including the British Pound and Euro. In addition, were non-recurring legal expenses of $175,000 related to the URT1 acquisition and financing. After adjusting for these numbers, management estimates total operating costs of $1,333,671 for the period. In addition to these expenditures, the Company has also incurred costs associated with positioning the business for scalability and the administration of its public listing.
  • Comprehensive loss of $(897,072) (Q1 2016 – $(125,644)). Going forward, management anticipates sales growth to strengthen from organic revenue generation and completed acquisitions, cost of sales to reduce due to higher volume purchases and optimization of the product portfolio, and operating costs to reduce as a result of normalized operations, which management anticipates to result in profitability and positive cash flow generation in fiscal 2017.

Management Commentary

Sean Dollinger, President and CEO of Namaste, comments: “The first quarter of 2017 represents substantial financial progress. In the first quarter, our team obtained these results while integrating multiple acquisitions and fulfilling orders during some of our most active months. Going forward, we continue to streamline operations, including optimizing our websites, human resources, and distribution networks, and believe our financial results will continue to reflect the value we have created for shareholders.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Direct: +1 (786) 389 9771

Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors 5 discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com
www.namastetechnologies.com

eSports: Facebook takes over from ESPN2 $GMBL

Posted by AGORACOM-JC at 3:08 PM on Thursday, January 26th, 2017
Arizona State's 2016 "Heroes of the Dorm" national championship computer gaming team during the final game.
  • “Facebook provides a great opportunity to offer this experience to new viewers around the globe and with a new level of engagement,” said Blizzard’s college eSports lead Adam Rosen. “We were very happy with the two years spent working with ESPN on the program and look forward to another great year with Facebook.”

Arizona State’s 2016 “Heroes of the Dorm” national championship computer gaming team… more

“Facebook provides a great opportunity to offer this experience to new viewers around the globe and with a new level of engagement,” said Blizzard’s college eSports lead Adam Rosen. “We were very happy with the two years spent working with ESPN on the program and look forward to another great year with Facebook.”

A Facebook spokesperson said the social media site will enable viewers to engage with each other around the world in real time in addition to providing statistics, team and player profiles.

Heroes of the Dorm is structured like the NCAA basketball season. The regular season, or group play, happens on the last two weekends of February and the first weekend of March. Regional competition takes place March 4-9 to narrow the field to 64 five-player teams, the same number as the NCAA tournament.

At that point teams are put into a single-elimination bracket that leads to the “Heroic Four” and national championship, both played on April 8.

College students have begun registering for this year’s competition, which was won in 2015 by UC Berkeley and last year by Arizona State. This year’s tournament includes $500,000 in scholarships and prizes.

Source: http://www.bizjournals.com/sanjose/news/2017/01/26/esports-new-deal-facebook-takes-over-from-espn2.html

HPQ Silicon Achieves 9,000 % Increase in Bench Test sample size; 300 % Increase in Capacity of Lab Scale PUREVAP(tm) $HPQ.ca

Posted by AGORACOM-JC at 8:13 AM on Thursday, January 26th, 2017

Hpq large

  • Chairman and CEO of HPQ-Silicon stated, “Demonstrating the scalability, at lab scale, of the PUREVAPtm QRR process in a repeatable and predictable manner while obtaining consistent purity results of 99.9+% (3N+)1 Si using 98.14% or less (1N) SiO2 feedstock
  • Represents yet another important technical milestones in in our progress toward production of High Purity Silicon metal

January 26, 2017 / TheNewswire / Montreal, Quebec, Canada – HPQ Silicon Resources Inc (“HPQ”) (TSX Venture: HPQ) is pleased to inform its shareholders that PyroGenesis Canada Inc (“PyroGenesis”) has submitted a new stage report entitled “Update on The PUREVAP Process Characterization Testing Phase” pertaining to 36 of 50 tests completed to date. The findings are significant in that they demonstrate the success of bench scale test work in scaling up the process of converting low purity feedstock into higher purity silicon metal.

Bernard Tourillon, Chairman and CEO of HPQ-Silicon stated, “Demonstrating the scalability, at lab scale, of the PUREVAPtm QRR process in a repeatable and predictable manner while obtaining consistent purity results of 99.9+% (3N+)1 Si using 98.14% or less (1N) SiO2 feedstock, represents yet another important technical milestones in in our progress toward production of High Purity Silicon metal. At this stage of our development, we have passed the critical milestones of consistently increasing sample size and now work will focus on improving the purity of the final product. This ‘iterative’ approach of incrementally increasing size, and purity step by step will continue and has so far been highly successful”.

TESTING CONFIRMS LAB SCALE SCALABILITY OF PUREVAP(TM) QRR PROCESS

The report confirms the scalability of the Process, explaining that in order to improve the yield of High Purity Silicon Metal (99.9+% Si) produced per batch, the lab-scale PUREVAPtm QRR reactor was successfully modified and capacity scaled up by a factor of 3 (300%). As a result, yield went from less than 0.1 g to 8.8 g (test #32), an increase of approximately 9,000% (hundredfold).

Of significant interest is the fact that all these results were obtained using lower purity feedstock (98.14% or less SiO2) than used by the Silicon Metal industry to produce Metallurgical Grade Silicon Metal (98.5% Si). Moreover, the results suggest that HPQ PUREVAP(TM) QRR PROCESS is the only process in the world that can systematically produce Silicon Metal of a purity above 3N+ (99.9+% Si) from sub-standard purity feed quartz.

“We are extremely pleased with the progress to date,” said Pierre Carabin, CTO of PyroGenesis. “Our ability to increase capacity by a factor of nearly hundredfold in such a short time gives us great confidence in scaling up the process to the 200 TPY pilot phase”.

INCREASING PURITY TO SOLAR GRADE SI (5N+) NOW BECOMES KEY FOCUS IN FINAL 14 TESTS

During the Proof of Concept phase, only high-purity quartz (99.97% SiO2) was used, while low-purity quartz (maximum 98.4%) was used for the other 36 tests. Moving forward, some tests will be conducted using higher purity feed stock (99.5% SiO2) in order to study the effect of reducing impurity at the source.

Test 19 confirmed that by adding a solid purifying agent into the feedstock, the production of 4N+ purity Silicon Metal (99.99+% Si)2 using 98.14% SiO2 was reachable. The engineering team at Pyrogenesis will continue to evaluate results and make process modifications to the PUREVAP(TM) QRR therefore allowing us to find the optimal purification process.

“Producing Solar Grade Silicon Metal remains our primary objective. For the remaining 14 tests, our intention is to focus solely on improving purity, with a goal of producing minimum 5N Si material,” said Tourillon. “In addition, PyroGenesis will also test an alternative route to higher purity during the ongoing test work.”

The R&D lab testing is still ongoing and the project is on schedule for end of February 2017 completion. By the end of the Process Characterization phase, PyroGenesis expects to have conducted 50 laboratory scale experiments. The data collected during the Process Characterization phase is being used for the Pilot Scale design, which is also currently underway.

VISUALIZING RAMP UP YIELD – RESULTS FROM TEST #24 – 32

Figure 1 – Small bead produced during test #24
Click Image To View Full Size

Figure 2 – Series of chunks produced during test #32

Pierre Carabin, Eng., M. Eng., has reviewed and approved the technical content of this press release.

About HPQ Silicon

HPQ Silicon Resources Inc is a TSX-V listed junior exploration company planning to become a vertically integrated and diversified High Value Silicon Metal (99.9+% Si), and Solar Grade Silicon Metal (99.999+% Si) producer.

Our business model is focused on developing a disruptive High Purity and Solar Grade Silicon Metal manufacturing process (patent pending) and becoming a vertically – integrated High Value Silicon Metal and Solar Grade Silicon producer that can generate high yield returns and significant free cash flow within a relatively short time line.

Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman and CEO Tel (514) 907-1011
Patrick Levasseur, President and COO Tel: (514) 262-9239
www.HPQSilicon.com

1 Analyses completed at the << Centre de Caracterisation Microscopique des Materiaux >> (CM2), located at the Ecole Polytechnique de
Montreal using a Scanning Electron Microscope (SEM) associated with a Wavelength-Dispersive Spectroscopy (WDS)

2